Cell Source, Inc. (CLCS)
OTCMKTS · Delayed Price · Currency is USD
0.9900
+0.1400 (16.47%)
Mar 5, 2026, 4:00 PM EST
Cell Source Market Cap
Cell Source has a market cap or net worth of $41.5 million as of March 5, 2026. Its market cap has increased by 108.57% in one year.
Market Cap
41.50M
Enterprise Value
51.57M
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
$0.99
Market Cap Chart
Since July 1, 2014, Cell Source's market cap has increased from 36.03M to 41.50M, an increase of 15.17%. That is a compound annual growth rate of 1.22%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 4, 2026 | 41.50M | 70.00% |
| Dec 31, 2025 | 24.41M | 59.96% |
| Dec 31, 2024 | 15.26M | -14.98% |
| Dec 27, 2023 | 17.95M | -40.09% |
| Dec 29, 2022 | 29.96M | -30.67% |
| Dec 31, 2021 | 43.22M | -32.39% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 27, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 20, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 27, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| HST Global | 70.56M |
| Nuo Therapeutics | 67.60M |
| Vicapsys Life Sciences | 48.56M |
| Arch Biopartners | 38.82M |
| ZIVO Bioscience | 37.00M |
| Harvard Apparatus Regenerative Technology | 30.77M |
| Finch Therapeutics Group | 21.28M |
| Provectus Biopharmaceuticals | 20.59M |